27.04.2012 - Zeltia Group has received €19m from its partner Johnson & Johnson. Progress with the cancer drug Yondelis triggered the milestone payment.
Madrid – Zeltia’s oncology subsidiary PharmaMar S.A. has received a second €19m milestone payment from Yondelis (trabectedin) ex-Europe partner Janssen, a Johnson & Johnson company. This follows the December 2011 receipt of €19m paid on agreement of a new US development plan. In late December 2011, PharmaMar reached the agreement with J&J subsidiary Janssen to push forward the development of Yondelis (trabectedin) in the US, with studies using the anti-tumour drug for the treatment of recurrent ovarian cancer and L-sarcoma.
Under the terms of the agreement, PharmaMar received a first €19m milestone payment at the end of 2011. On top of the actual €19m payment further €60m of milestones may fall due in 2013/2015, in addition to the economics agreed at the time of the original license. The PharmaMar mother company is approaching additional key pipeline catalysts, with an interim analysis of the ADMYRE study of Aplidin in relapsed/refractory multiple myeloma expected soon. An interim analysis of the Phase II PM01183 trial in resistant ovarian cancer and results of a Phase II study of Nypta (tideglusib) in Alzheimer’s disease, are both due at the end of the year. Yondelis is already marketed for the treatment of advanced soft tissue sarcoma and ovarian cancer in Europe, Russia and South Korea. Yondelis sales growth to €80m (+12%) in 2011 was hampered by supply issues with Doxil, with which it is administered in ovarian cancer. However Yolendis sales declined in Q1/2012 compared to the first quarter in 2011.
04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.
03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.
29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.
27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).
21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.
21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.
19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.
15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.
13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.